Dermatology and Therapy最新文献

{"title":"Correction: Effectiveness and Tolerability of Low-Dose Micronized Isotretinoin in Patients with Severe Recalcitrant Nodular Facial Acne in India: A Real-World Retrospective Study Using Electronic Medical Records.","authors":"Byalakere S Chandrashekar, Maya Vedamurthy, Seetharamanjaneyulu Kolalapudi, Vijaya Bhaskar Mallela, Shahnaz Arsiwala, Anil Ganjoo, Abir Saraswat, Farida Modi, Sowmya C Sujatha, Satish Udare, Surajit Gorai, Mukesh Gabhane, Bhavesh Lalan, Gaurang Jani, Aditi Jain, Shruti Dharmadhikari, Chintan Khandhedia, Prashant Devkare, Amey Mane, Asif Shaikh, Suyog Mehta","doi":"10.1007/s13555-026-01904-w","DOIUrl":"https://doi.org/10.1007/s13555-026-01904-w","url":null,"abstract":"","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2026-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148896736","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Use of Adjuvant Nivolumab for Resected Stage III-IV Melanoma: 2-Year Analysis of AdjuMel.","authors":"Stéphane Dalle, Philippe Saiag, Céleste Lebbé, Jean-Jacques Grob, Brigitte Dréno, Sophie Dalac, Bernard Asselain, François Skowron, Sophie Darras, Nicolas Jovenin, Gaëlle Quereux, Amir Khammari, Capucine Rieuf, Florence Brellier, Laurent Mortier","doi":"10.1007/s13555-026-01853-4","DOIUrl":"https://doi.org/10.1007/s13555-026-01853-4","url":null,"abstract":"<p><strong>Introduction: </strong>Following the positive findings of the phase 3 CheckMate 238 trial, adjuvant nivolumab has become a standard therapy in patients with completely resected stage III-IV melanoma. The prospective, ongoing AdjuMel study is evaluating the real-world use, effectiveness, and safety of adjuvant nivolumab in patients with resected melanoma in France. Here we report 2-year results from the third interim analysis of AdjuMel.</p><p><strong>Methods: </strong>This observational, prospective study is evaluating data from patients with resected stage III-IV melanoma treated with adjuvant nivolumab in France. Study outcomes include effectiveness, safety, and treatment patterns of anti-programmed cell death-1 (PD-1, nivolumab) under routine clinical practice in the adjuvant setting. The primary endpoint was relapse-free survival (RFS). This third interim analysis (data cut-off: 3 November 2023) included patients with ≥ 1 follow-up visit, using data collected up to the 24-month visit.</p><p><strong>Results: </strong>Overall, 343 patients (median [range] age 65 [27-95] years; 57.7% male; 41.7% BRAF-mutation positive) were evaluable in this interim analysis, with a median (range) follow-up of 23.4 (2.1-27.3) months. At treatment initiation, 86.8% and 13.2% of patients had stage III and IV disease, respectively. The 2-year RFS rate was 52.8% (95% confidence interval 47.0-58.2). The risk of recurrence or death was lower in patients with stage IIIA disease versus IIIB-D (hazard ratio [HR] 0.43) and in those aged < 75 versus ≥ 75 years (HR 0.56), and higher in patients with versus without tumor ulceration (HR 1.99). The safety profile of adjuvant nivolumab was consistent with that reported in CheckMate 238, and patient quality of life did not appear to be adversely affected.</p><p><strong>Conclusions: </strong>These real-world data are in line with those reported in randomized clinical trials, despite the broader inclusion criteria of the study population.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov identifier: NCT04550247.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2026-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148857164","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expert Consensus on the Role of Dermocosmetics in Acne Management in the United Arab Emirates.","authors":"Ahmed Ameen, Ayman Alnaeem, Ahmed Aldhaheri, Ashraf Reda, Fatima Albreiki, Huda Rajab Ali, Hussein Abdel Dayem, Jawaher Alnaqbi, Mariam Al Suwaidi, Meera Al Adawi, Raghda Al Maashari, Sahar Al Nowais, Jerry Tan, Muna Al Murrawi","doi":"10.1007/s13555-026-01903-x","DOIUrl":"https://doi.org/10.1007/s13555-026-01903-x","url":null,"abstract":"<p><strong>Introduction: </strong>Acne is a chronic inflammatory skin disorder with multiple pathogenic pathways. The aim of this initiative was to develop United Arab Emirates (UAE)-specific consensus statements supporting the clinical integration of dermocosmetics into acne management.</p><p><strong>Methods: </strong>An expert panel comprising 13 eminent dermatologists practicing in the UAE completed a pre-meeting survey on local acne management practices, followed by a meeting to appraise the proposed consensus statements. Consensus required a ≥ 70% level of agreement through anonymous online voting.</p><p><strong>Results: </strong>According to the pre-meeting survey, most patients with acne were aged 13-35 years. Acne-induced hyperpigmentation and scarring were the most common complications. Despite their potential benefits, dermocosmetics were underutilized in routine clinical practice. Some dermocosmetics contain dermatologically active ingredients with clinical evidence supporting benefits in acne-prone skin, particularly for barrier support, tolerability, oil control, photoprotection, maintenance, and adherence. In total, the expert panel developed seven consensus statements that endorsed the value of dermocosmetics as: (1) initial therapy in mild acne, (2) adjuvant therapy to enhance tolerability and adherence in moderate-to-severe acne, and (3) maintenance therapy to sustain remission and prevent relapse. They highlighted its benefits in acne-induced hyperpigmentation, especially in darker phototypes and oilier skin phenotypes, which are common in the UAE. Additionally, the expert panel advocated for individualized treatment strategies according to the need, skin type, and acne severity of each patient.</p><p><strong>Conclusion: </strong>To our knowledge, this represents the first UAE-specific consensus guiding the integration and standardization of dermocosmetics into acne management. The statements are aligned to international standards and can be adapted to other regions sharing similar characteristics as UAE.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2026-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148850163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dual-Targeted Therapy in Refractory Pyoderma Gangrenosum: A Focused Systematic Review of Convergent Pathway Targeting.","authors":"Mohammed Shanshal, George Karanasios","doi":"10.1007/s13555-026-01895-8","DOIUrl":"https://doi.org/10.1007/s13555-026-01895-8","url":null,"abstract":"<p><strong>Background: </strong>Refractory pyoderma gangrenosum (PG) may persist despite corticosteroids, ciclosporin, biologics or sequential treatment escalation. Dual-targeted therapy (DTT) is increasingly used in medically complex inflammatory bowel disease (IBD), but PG is often recorded only as an extraintestinal manifestation. We examined the direction, extractability and attribution limits of PG outcomes reported during concurrent DTT.</p><p><strong>Methods: </strong>PubMed, Embase via Ovid and Web of Science Core Collection were searched from inception to 26 July 2026. Eligible reports described at least one patient with PG receiving concurrent systemic DTT, defined as biologic-biologic, biologic-Janus kinase (JAK) inhibitor or biologic-phosphodiesterase-4 inhibitor combinations. Screening and extraction were performed independently and in duplicate. The analytic unit was the PG exposure. Outcomes were retained as source-reported and were not pooled because PG assessment, follow-up and co-intervention reporting were non-standardised.</p><p><strong>Results: </strong>Fourteen reports described 17 PG exposures. Of these, 14 had an extractable PG-specific cutaneous outcome, all source-reported using non-standardised assessments as improved or resolved. This 14-of-14 pattern reflects the direction of published outcome-bearing observations, not a denominator-based response estimate. Three additional cohort-level records documented PG exposure without a separable cutaneous end-point. A total of 16 exposures were IBD-associated and 11 involved JAK-containing regimens. Individual regimen mapping, diagnostic ascertainment, follow-up and co-intervention reporting were frequently incomplete. All evidence was uncontrolled, safety reporting was limited and the complete exposure denominator was unknown.</p><p><strong>Conclusions: </strong>Favourable PG outcomes were reported across several DTT pathway pairings, but these uncontrolled published observations do not establish efficacy, comparative advantage or added benefit from simultaneous pathway blockade. The next step is a dermatology-embedded prospective registry within IBD DTT programmes, with standardised PG diagnosis, lesion documentation, co-intervention recording and exposure-specific safety ascertainment. Until such evidence is available, DTT should remain an exceptional multidisciplinary consideration rather than an established PG treatment strategy.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2026-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148850145","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Three-Year Efficacy and Safety of Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Long-Term Extension (ADjoin).","authors":"Emma Guttman-Yassky, Alan D Irvine, Melinda Gooderham, Stephan Weidinger, Lynda Spelman, Jonathan I Silverberg, Heidi Crane, Hany ElMaraghy, Louise DeLuca-Carter, Maria Lucia Buziqui Piruzeli, Georgia Martimianaki, Evangeline Pierce, Helena Agell, Diamant Thaçi","doi":"10.1007/s13555-026-01876-x","DOIUrl":"https://doi.org/10.1007/s13555-026-01876-x","url":null,"abstract":"","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2026-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148850078","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prophylactic Medium-Class Topical Steroids are Associated with a Lower Incidence of Capecitabine-Induced Hand-Foot Syndrome in Patients with Colorectal Cancer.","authors":"Yohei Iimura, Yuka Ahiko, Satoko Monma, Naoki Sakuyama, Susumu Aikou, Dai Shida, Seiichiro Kuroda","doi":"10.1007/s13555-026-01898-5","DOIUrl":"https://doi.org/10.1007/s13555-026-01898-5","url":null,"abstract":"<p><strong>Introduction: </strong>There is limited clinical research evaluating the role of topical corticosteroids in preventing hand-foot syndrome (HFS) caused by capecitabine. Although the precise cause of HFS remains unclear, inflammatory mechanisms are thought to contribute to its development. This study investigated whether prophylactic use of a medium-class topical corticosteroid was associated with a lower incidence of capecitabine-related HFS in patients with colorectal cancer.</p><p><strong>Methods: </strong>We retrospectively assessed 78 patients prescribed medium-class topical steroids as a preventive against HFS associated with capecitabine and 32 topical steroid-free patients undergoing capecitabine-based chemotherapy. We evaluated the incidence of each grade of HFS during chemotherapy.</p><p><strong>Results: </strong>Between January 2022 and March 2025, 110 patients were enrolled in the study. Grade ≥ 2 HFS occurred in 23.1% of patients in the medium-class topical steroid group and 50.0% of patients in the topical steroid-free group (OR, 0.30; 95% CI 0.13-0.72; P = 0.012, Fisher's exact test). The incidence of other capecitabine-related adverse events did not differ significantly between the groups.</p><p><strong>Conclusion: </strong>Our findings suggest that prophylactic use of medium-class topical steroids was associated with a lower incidence of capecitabine-induced hand-foot syndrome. Prospective randomized studies are warranted to confirm these findings.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2026-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148849606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Elongated Corkscrew Hairs as a Possible Novel Trichoscopic Sign in Endothrix Tinea Capitis Affecting Adults with Immunosuppression.","authors":"Asmahane Souissi, Raquel de Melo Carvalho, Malek Ben Slimane, Mohammad Jafferany, Daniel Fernandes Melo","doi":"10.1007/s13555-026-01902-y","DOIUrl":"https://doi.org/10.1007/s13555-026-01902-y","url":null,"abstract":"<p><strong>Introduction: </strong>Tinea capitis is a fungal infection of the scalp in which trichoscopy plays an important role by allowing early identification of characteristic hair shaft alterations before mycological confirmation.</p><p><strong>Methods: </strong>We describe two adult women who are immunosuppressed with endothrix tinea capitis caused by Trichophyton violaceum.</p><p><strong>Results: </strong>Both patients presented with diffuse scalp alopecia and scaling. Trichoscopic examination revealed unusually elongated corkscrew hairs, and fungal cultures confirmed the diagnosis.</p><p><strong>Conclusions: </strong>Elongated corkscrew hairs represent a previously unreported trichoscopic pattern in chronic endothrix tinea capitis. Awareness of this finding may facilitate earlier diagnostic suspicion and prompt targeted mycological investigation in patients who are immunosuppressed.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2026-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148850099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Effectiveness and Safety of Bimekizumab for Moderate-to-Severe Hidradenitis Suppurativa: A Multicenter Retrospective Study from the Italian Landscape HS (IL-HS).","authors":"Mario Valenti, Ruggero Cascio Ingurgio, Luciano Ibba, Edoardo Cammarata, Raffaele D Caposiena Caro, Andrea Carugno, Martina Dragotto, Claudio Marasca, Piergiorgio Malagoli, Fabrizio Martora, Angelo V Marzano, Matteo Megna, Santo R Mercuri, Francesco Messina, Alessandra Michelucci, Chiara Moltrasio, Giovanni Paolino, Federica Repetto, Simone Ribero, Luigi Rossiello, Emanuele Trovato, Nicola Zerbinati, Antonio Costanzo, Alessandra Narcisi, Valentina Dini","doi":"10.1007/s13555-026-01891-y","DOIUrl":"https://doi.org/10.1007/s13555-026-01891-y","url":null,"abstract":"<p><strong>Introduction: </strong>Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease characterized by painful nodules, abscesses, draining tunnels and substantial impairment in quality of life. Bimekizumab, a monoclonal antibody that selectively inhibits interleukin-17A and interleukin-17F, was recently approved in Italy for the treatment of moderate-to-severe HS. However, real-world evidence remains limited.</p><p><strong>Methods: </strong>This was a retrospective multicenter study of patients with HS treated with bimekizumab across Italian dermatology referral centers. Effectiveness was assessed at weeks 4, 16 and 24 using the following measurement tools and scales: Hidradenitis Suppurativa Clinical Response (HiSCR), HiSCR75, HiSCR90, HiSCR100 (at least 75%, 90% and 100% reductions in AN count, respectively, plus HiSCR criteria), the International Hidradenitis Suppurativa Severity Score System 55% reduction (IHS4-55), International Hidradenitis Suppurativa Severity Score System (IHS4), draining tunnel count, abscess and inflammatory nodule (AN) count, AN50 (at least 50% reduction in AN), pain numerical rating scale (NRS-pain), NRS50 (as at least a 50% reduction in NRS-pain compared with baseline) and Dermatology Life Quality Index (DLQI). Safety outcomes included adverse events, rescue therapies and concomitant treatments.</p><p><strong>Results: </strong>A total of 100 patients were included in the study among whom 56% were male and the mean age was 37.3 years. Median body mass index was 26.8 kg/m², 75% had Hurley stage III disease and 80% had prior biologic exposure. HiSCR was achieved by 36 of 100 (36.0%) patients at week 4, 60 of 100 (60.0%) patients at week 16 and 41 of 53 (77.4%) patients at week 24. HiSCR75 was achieved by 24 of 100 (24.0%) patients, 48 of 100 (48.0%) patients and 35 of 53 (66.0%) patients at weeks 4, 16 and 24, respectively. Median IHS4 decreased from 18 at baseline to 7 at week 24; median draining tunnel count decreased significantly from baseline at all visits, median AN count decreased from 3.5 to 1, median NRS-pain decreased from 8 to 3, and median DLQI decreased from 19.5 to 7. IHS4-55 was achieved by 54.7% of evaluable patients at week 24. Flare rates remained below 10% throughout follow-up. Any adverse event was reported in 22 patients (22.0%).</p><p><strong>Conclusion: </strong>In this multicenter Italian real-world cohort, bimekizumab was associated with early clinical improvement and meaningful reductions in disease activity, pain and quality-of-life burden; week-24 estimates should be interpreted in light of administrative censoring.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2026-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148849843","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety of Icotrokinra Through 1 Year for the Treatment of Moderate-to-Severe Plaque Psoriasis and Psoriasis Affecting High-Impact Sites: Pooled Results Across the ICONIC-LEAD, ICONIC-TOTAL, and ICONIC-ADVANCE 1 and 2 Phase 3 Trials.","authors":"Mark G Lebwohl, Melinda Gooderham, Richard B Warren, Lawrence F Eichenfield, Jessica H Rubens, Tracy Cardillo, Christopher Russo, Cynthia M C DeKlotz, Megan Miller-Kassamali, Luis Anaya Velarde, Ming-Chun Hsu, Shu Li, Ya-Wen Yang, Sarah Ofori, Robert Bissonnette, Jennifer Soung, Adelaide A Hebert, Linda Stein Gold","doi":"10.1007/s13555-026-01885-w","DOIUrl":"https://doi.org/10.1007/s13555-026-01885-w","url":null,"abstract":"<p><strong>Introduction: </strong>Icotrokinra, a first-in-class targeted oral peptide, precisely blocks the interleukin (IL)-23 receptor and inhibits IL-23 pathway signaling. In phase 3 studies (ICONIC-LEAD, ICONIC-TOTAL, ICONIC-ADVANCE 1 and 2), icotrokinra provided superior skin clearance versus placebo and deucravacitinib in adults and adolescents with moderate-to-severe psoriasis and psoriasis affecting high-impact sites. This analysis evaluates icotrokinra safety through 1 year using pooled data from these four studies.</p><p><strong>Methods: </strong>Icotrokinra-randomized participants received 200-mg pills once daily, and placebo-randomized participants crossed over to icotrokinra at week 16; participants randomized to deucravacitinib 6 mg (ICONIC-ADVANCE 1 and 2 only) switched to icotrokinra at week 24. Pooled safety data are summarized for the placebo-controlled period (week 0-16, all studies), active-controlled period (week 0-24, ICONIC-ADVANCE 1 and 2), and through week 52 (all studies).</p><p><strong>Results: </strong>During the placebo-controlled period across all studies, 568 participants received placebo and 1296 received icotrokinra. From week 0 to 24 in the ICONIC-ADVANCE studies, 632 participants received icotrokinra and 634 received deucravacitinib. Through week 52, 2400 icotrokinra-treated participants contributed 1840 participant-years [PY] of follow-up. Through week 16, in the icotrokinra and placebo groups, respectively, exposure-adjusted incidence rates/100 PY of adverse events (AEs; 232 and 269), serious AEs (5.2 and 6.6), infections (91 and 104), and AEs leading to discontinuation (6.6 and 10.0) were comparable between groups. Through week 24, in the ICONIC-ADVANCE studies, rates/100 PY with icotrokinra versus deucravacitinib were as follows: AEs, 204 vs 265; serious AEs, 6.4 vs 7.2; infections, 81 vs 119; AEs leading to discontinuation, 5.7 vs 6.8. Through week 52, event rates/100 PY in icotrokinra-treated participants were as follows: AEs, 167; serious AEs, 4.6; infections, 76; AEs leading to discontinuation, 3.0.</p><p><strong>Conclusion: </strong>In this analysis of 2400 icotrokinra-treated participants with psoriasis followed through 1 year, icotrokinra demonstrated favorable safety; event rates through week 16 were similar to placebo and remained consistent through week 52.</p><p><strong>Clinicaltrials: </strong>GOV: NCT06095115, NCT06095102, NCT06143878, NCT06220604. Infographic available for this article. INFOGRAPHIC.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2026-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148849814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Emerald Touchless Sensor Quantifies Nighttime Scratching and Sleep Quality in Children With Atopic Dermatitis: PEDISTAD EMERALD Study.","authors":"Cory J Rubin, Lara W Lee, Amal Assa'ad, Irene Lara-Corrales, Dina Katabi, Hariharan Rahul, Siqiao Ruan, Pranav Krishna, Rumen Hristov, Karen J Chandross, Rajan Gupta, Marius Ardeleanu, Annie Zhang","doi":"10.1007/s13555-026-01864-1","DOIUrl":"https://doi.org/10.1007/s13555-026-01864-1","url":null,"abstract":"<p><strong>Introduction: </strong>In children with atopic dermatitis (AD), itch-related nighttime scratching is associated with significant sleep disturbances. The aim of this study is to report the feasibility of using the Emerald touchless sensor to quantify nighttime scratching and sleep patterns in pediatric patients.</p><p><strong>Methods: </strong>PEDISTAD EMERALD (NCT05235724), an open-label, 12-week, exploratory study, included 20 pediatric patients with moderate-to-severe AD aged 6-11 years from the PEDISTAD registry (NCT03687359). The Emerald touchless sensor measures sleep onset and efficiency. Correlation analyses were performed between sleep onset and Peak Pruritus Numeric Rating Scale (PP-NRS), scratching events and time per hour and PP-NRS, and weekly averages of nightly scratching events per hour and sleep efficiency.</p><p><strong>Results: </strong>We show strong statistically significant correlations between sleep onset and PP-NRS (Pearson correlation coefficient: r = 0.50; p = 0.049) and between scratching events per hour and sleep efficiency (r = - 0.66; p = 0.003). Additionally, we observed positive correlations between scratching events (r = 0.46; p = 0.076) and scratching time per hour (r = 0.43; p = 0.096) and PP-NRS that did not reach statistical significance.</p><p><strong>Conclusions: </strong>The Emerald touchless sensor can provide objective measures of itch-related scratching and sleep disturbance in children with AD in a home setting, demonstrating its feasibility for use in pediatric clinical trials.</p><p><strong>Trial registration: </strong>NCT05235724.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2026-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148817434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}